Cantargia AB   Report issue

For profit Phase 1 Phase 2
Founded: Lund Sweden (2010)

Organization Overview

First Clinical Trial
2017
NCT03267316
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Cantargia AB | Chief Medical Officer, Cantargia AB